<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-5274</journal-id>
<journal-title><![CDATA[Clínica y Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Clínica y Salud]]></abbrev-journal-title>
<issn>1130-5274</issn>
<publisher>
<publisher-name><![CDATA[Colegio Oficial de la Psicología de Madrid]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-52742019000200005</article-id>
<article-id pub-id-type="doi">10.5093/clysa2019a14</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Long-term negative psychological impact of presymptomatic testing on familial amyloid polyneuropathy]]></article-title>
<article-title xml:lang="es"><![CDATA[Efecto psicológico negativo a largo plazo de las pruebas genéticas presintomáticas en la polineuropatía amiloide familiar]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Teixeira Leite]]></surname>
<given-names><![CDATA[Ângela M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pimenta Dinis]]></surname>
<given-names><![CDATA[Maria Alzira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lêdo da Silva Pinto]]></surname>
<given-names><![CDATA[Susana M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pinheiro Gomes]]></surname>
<given-names><![CDATA[Ana I.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Baldaia Carvalho Pinto]]></surname>
<given-names><![CDATA[Ana M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidade Europeia  ]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="A02">
<institution><![CDATA[,University of Fernando Pessoa  ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Institute for Molecular and Cell Biology (IBMC)  ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="A04">
<institution><![CDATA[,Lusophone University of Oporto  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2019</year>
</pub-date>
<volume>30</volume>
<numero>2</numero>
<fpage>91</fpage>
<lpage>97</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-52742019000200005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-52742019000200005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-52742019000200005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT This study addresses the profile of at-risk subjects whose long-term psychological impact of presymptomatic testing (PST) for Familial Amyloid Polyneuropathy (FAP) TTR V30M is negative. The sample consisted of 177 subjects, aged over 20 years that were 50% at-risk for FAP, and performed the PST at least three years ago. Participants were contacted by mail, one time only, to answer the sociodemographic questionnaire and the Brief Symptom Inventory (BSI), the Self-Rating Anxiety Scale of Zung (SAS), and the Beck Depression Inventory (BDI). From the sample, 22.6% (BSI), 16.4% (SAS), and 9% (BDI) subjects presented negative psychological impact, after having performed the PST for more than 3 years. Subjects with clinically significant values in BSI, SAS, and BDI have an overlapping profile concerning the total sample, except regarding age, since clinically depressed subjects have a higher mean age. Married women or living in unmarried unions, aged between 30 and 45 years, employed, carriers, and having performed the PST test for 6-7 years are a group raising higher concern and requiring a more active role with respect to the psychological impact of the PST for FAP. The role of the clinical and health psychologist with these patients is critical in the adjustment to the presymptomatic test result as well as in adherence to the available treatments conducive to a better quality of life, in carriers.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Este estudio aborda el perfil de sujetos en riesgo cuyo impacto psicológico a largo plazo de las pruebas presintomáticas (PST) para la polineuropatía amiloide familiar (FAP) TTR V30M es negativo. La muestra consistió en 177 sujetos mayores de 20 años que tenían un 50% de riesgo de FAP, que habían realizado el PST hacía al menos tres años. Se contactó con los participantes por correo, solo una vez, para responder el cuestionario sociodemográfico y el Inventario de síntomas breves (BSI), la Escala de ansiedad de autoclasificación de Zung (SAS) y el Inventario de depresión de Beck (BDI). El 22.6% (BSI), el 16.4% (SAS) y el 9% (BDI) de los sujetos de la muestra presentaron un impacto psicológico negativo después de haber realizado el PST durante más de 3 años. Los sujetos con valores clínicamente significativos en BSI, SAS y BDI tienen un perfil superpuesto con respecto a la muestra total, excepto con respecto a la edad, ya que los sujetos clínicamente deprimidos tienen una edad media más alta. Las mujeres casadas o que viven en pareja, con edades entre 30 y 45 años, que trabajan, son portadoras y han realizado la prueba PST durante 6-7 años son un grupo que suscita una mayor preocupación y requiere un papel más activo con respecto al impacto psicológico del PST para FAP. El papel del psicólogo clínico y de la salud con estos pacientes es decisivo en el ajuste del resultado de la prueba presintomática, así como en la adhesión a los tratamientos disponibles que conducen a una mejor calidad de vida en los portadores.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Presymptomatic Testing (PST)]]></kwd>
<kwd lng="en"><![CDATA[Familial Amyloid Polyneuropathy (FAP) TTR V30M]]></kwd>
<kwd lng="en"><![CDATA[Long-term Psychological Impact]]></kwd>
<kwd lng="en"><![CDATA[Brief Symptom Inventory (BSI)]]></kwd>
<kwd lng="en"><![CDATA[Zung Self-Rating Anxiety Scale (SAS)]]></kwd>
<kwd lng="en"><![CDATA[Beck Depression Inventory (BDI)]]></kwd>
<kwd lng="es"><![CDATA[Pruebas presintomáticas (PST)]]></kwd>
<kwd lng="es"><![CDATA[Polineuropatía amiloide familiar (FAP) TTR V30M]]></kwd>
<kwd lng="es"><![CDATA[Impacto psicológico a largo plazo]]></kwd>
<kwd lng="es"><![CDATA[Inventario de síntomas breves (BSI)]]></kwd>
<kwd lng="es"><![CDATA[Escala de autoclasificación de ansiedad de Zung (SAS)]]></kwd>
<kwd lng="es"><![CDATA[Inventario de depresión de Beck (BDI)]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Familial amyloid polyneuropathy]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almqvist]]></surname>
<given-names><![CDATA[E. W]]></given-names>
</name>
<name>
<surname><![CDATA[Brinkman]]></surname>
<given-names><![CDATA[R. R]]></given-names>
</name>
<name>
<surname><![CDATA[Wiggins]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hayden]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
</person-group>
<collab>Canadian Collaborative Study of Predictive Testing</collab>
<article-title xml:lang=""><![CDATA[Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease]]></article-title>
<source><![CDATA[Clinical Genetics]]></source>
<year>2003</year>
<volume>64</volume>
<page-range>300-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Austin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Semaka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hadjipavlou]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Conceptualizing genetic counseling as psychotherapy in the era of genomic medicine]]></article-title>
<source><![CDATA[Journal of Genetic Counseling]]></source>
<year>2014</year>
<volume>23</volume>
<page-range>903-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[A. T]]></given-names>
</name>
<name>
<surname><![CDATA[Steer]]></surname>
<given-names><![CDATA[R. A]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[G. K.]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual for the Beck Depression Inventory&#8211;II]]></source>
<year>1996</year>
<publisher-loc><![CDATA[San Antonio, TX ]]></publisher-loc>
<publisher-name><![CDATA[Psychological Corporation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[A. T]]></given-names>
</name>
<name>
<surname><![CDATA[Ward]]></surname>
<given-names><![CDATA[C. H]]></given-names>
</name>
<name>
<surname><![CDATA[Mendelson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Erbaugh]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An inventory for measuring depression]]></article-title>
<source><![CDATA[Archives of General Psychiatry]]></source>
<year>1961</year>
<volume>4</volume>
<page-range>561-71</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Canavarro]]></surname>
<given-names><![CDATA[M. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inventário de Sintomas Psicopatológicos: BSI]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Simões]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Gonçalves]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[L. S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Testes e provas psicológicas em Portugal]]></source>
<year>1999</year>
<volume>II</volume>
<page-range>87-109</page-range><publisher-loc><![CDATA[Braga, Portugal ]]></publisher-loc>
<publisher-name><![CDATA[SHO/APPORT]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Canavarro]]></surname>
<given-names><![CDATA[M. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inventário de Sintomas Psicopatológicos: Uma revisão crítica dos estudos realizados em Portugal]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Simões]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Gonçalves]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Avaliação psicológica: Instrumentos validados para a população Portuguesa]]></source>
<year>2007</year>
<volume>III</volume>
<page-range>305-31</page-range><publisher-loc><![CDATA[Coimbra, Portugal ]]></publisher-loc>
<publisher-name><![CDATA[Quarteto Editora]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Maia]]></surname>
<given-names><![CDATA[L. F]]></given-names>
</name>
<name>
<surname><![CDATA[Martins da Silva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Waddington]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Planté-Bordeneuve]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lozeron]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Grogan]]></surname>
<given-names><![CDATA[D. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2012</year>
<volume>79</volume>
<page-range>785-92</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Decruyenaere]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Evers-Kiebooms]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cloostermans]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Boogaerts]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Demyttenaere]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dom]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fryns]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychological distress in the 5-year period after predictive testing for Huntington's disease]]></article-title>
<source><![CDATA[European Journal of Human Genetics]]></source>
<year>2003</year>
<volume>11</volume>
<page-range>30-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Decruyenaere]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Evers-Kiebooms]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cloostermans]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Boogaerts]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Demyttenaere]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dom]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fryns]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictive testing for Huntington's disease: Relationship with partners after testing]]></article-title>
<source><![CDATA[Journal of Clinical Genetics]]></source>
<year>2004</year>
<volume>65</volume>
<page-range>24-31</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Derogatis]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Melisaratos]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Brief Symptom Inventory: An introductory report]]></article-title>
<source><![CDATA[Psychological Medicine]]></source>
<year>1983</year>
<volume>13</volume>
<page-range>595-605</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gargiulo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lejeune]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tanguy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lahlou-Laforet]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Faudet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Durr]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term outcome of presymptomatic testing in Huntington disease]]></article-title>
<source><![CDATA[European Journal of Human Genetics]]></source>
<year>2009</year>
<volume>17</volume>
<page-range>165-71</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gomes]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kazachkova]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bettencourt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Raposo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychological well-being and family satisfaction levels five years after being confirmed as a carrier of the Machado-Joseph disease mutation]]></article-title>
<source><![CDATA[Genetic Testing and Molecular Biomarkers]]></source>
<year>2012</year>
<volume>16</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lêdo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leite]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sequeiros]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anxiety and pre-symptomatic testing for neurodegenerative disorders]]></article-title>
<source><![CDATA[Open Journal of Genetics]]></source>
<year>2013</year>
<volume>3</volume>
<page-range>14-26</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lêdo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leite]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sequeiros]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Depression levels in pre-symptomatic testing for neurodegenerative diseases: A psychological point of view]]></article-title>
<source><![CDATA[Journal of Life Medicine]]></source>
<year>2014</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>39-50</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lêdo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leite]]></surname>
<given-names><![CDATA[Â]]></given-names>
</name>
<name>
<surname><![CDATA[Souto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dinis]]></surname>
<given-names><![CDATA[M. A. P]]></given-names>
</name>
<name>
<surname><![CDATA[Sequeiros]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Depression as the middle- and long-term impact for pre-symptomatic testing of late-onset neurodegenerative disorders]]></article-title>
<source><![CDATA[Trends in Psychology]]></source>
<year>2016</year>
<month>a</month>
<volume>24</volume>
<page-range>579-94</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lêdo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leite]]></surname>
<given-names><![CDATA[Â]]></given-names>
</name>
<name>
<surname><![CDATA[Souto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dinis]]></surname>
<given-names><![CDATA[M. A]]></given-names>
</name>
<name>
<surname><![CDATA[Sequeiros]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mid- and long-term anxiety levels associated with presymptomatic testing of Huntington's disease, Machado-Joseph disease, and familial amyloid polyneuropathy]]></article-title>
<source><![CDATA[Revista Brasileira de Psiquiatria]]></source>
<year>2016</year>
<month>b</month>
<volume>38</volume>
<page-range>113-20</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lêdo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leite]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Souto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dinis]]></surname>
<given-names><![CDATA[M. A. P]]></given-names>
</name>
<name>
<surname><![CDATA[Sequeiros]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pre-symptomatic testing for HD, MJD and FAP neurodegenerative disorders: Middle- to long-term psychopathological impact]]></article-title>
<source><![CDATA[Psychothema]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lêdo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Paneque]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Leite]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sequeiros]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictive testing for two neurodegenerative disorders (FAP and HD): A psychological point of view]]></article-title>
<source><![CDATA[Open Journal of Genetics]]></source>
<year>2013</year>
<volume>3</volume>
<page-range>270-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nance]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic counseling and testing for Huntington's disease: A historical review]]></article-title>
<source><![CDATA[American Journal of Medical Genetics Part B: Neuropsychiatric Genetics]]></source>
<year>2017</year>
<volume>174</volume>
<page-range>75-92</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponciano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vaz Serra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Relvas]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aferição da escala de auto-avaliação de ansiedade, de Zung, numa amostra portuguesa &#8211; I &#8211; Resultados da aplicação numa amostra de população normal]]></article-title>
<source><![CDATA[Psiquiatria Clinica]]></source>
<year>1982</year>
<month>a</month>
<volume>3</volume>
<page-range>191-202</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponciano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vaz Serra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Relvas]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aferição da escala de auto-avaliação de ansiedade de Zung numa amostra portuguesa &#8211; II - Sua avaliação como instrumento de medida]]></article-title>
<source><![CDATA[Psiquiatria Clínica]]></source>
<year>1982</year>
<month>b</month>
<volume>3</volume>
<page-range>203-13</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tibben]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Timman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bannink]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Duivenvoorden]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Three years follow-up after presymptomatic testing for Huntington's Disease in tested subjects and partners]]></article-title>
<source><![CDATA[Journal of Health Psychology]]></source>
<year>1997</year>
<volume>6</volume>
<page-range>20-35</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Timman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Roos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Maat-Kievit]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tibben]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse effects of predictive testing for Huntington disease underestimated: Long-term effects 7-10 years after the test]]></article-title>
<source><![CDATA[Journal of Health Psychology]]></source>
<year>2004</year>
<volume>23</volume>
<page-range>189-97</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaz-Serra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Abreu]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aferição dos quadros clínicos depressivos I: Ensaio de aplicação do &#8220;Inventário Depressivo de Beck&#8221; a uma amostra portuguesa de doentes deprimidos]]></article-title>
<source><![CDATA[Coimbra Médica]]></source>
<year>1973</year>
<month>a</month>
<volume>20</volume>
<page-range>623-44</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaz Serra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pio Abreu]]></surname>
<given-names><![CDATA[J. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aferição dos quadros clínicos depressivos II: Estudo preliminar de novos agrupamentos sintomatológicos para complemento do Inventário Depressivo de Beck&#8221;]]></article-title>
<source><![CDATA[Coimbra Médica]]></source>
<year>1973</year>
<month>b</month>
<volume>20</volume>
<page-range>713-36</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wicklund]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Trepanier]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adapting genetic counseling training to the genomic era: More an evolution than a revolution]]></article-title>
<source><![CDATA[Journal of Genetic Counseling]]></source>
<year>2014</year>
<volume>23</volume>
<page-range>452-4</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zung]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A rating instrument for anxiety disorders]]></article-title>
<source><![CDATA[Psychosomatics]]></source>
<year>197</year>
<volume>12</volume>
<page-range>371-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
